Klinik für Neurochirurgie, Universitätsklinikum des Saarlandes, Homburg, Germany.
Klinik für Neurochirurgie, Universitätsklinikum des Saarlandes, Homburg, Germany.
Ann Anat. 2021 Sep;237:151752. doi: 10.1016/j.aanat.2021.151752. Epub 2021 Apr 30.
The use of photodynamic agents in malignant cranial tumor surgery is quite common. For example five-aminolevulinic acid (5-ALA)-induced porphyrins in malignant gliomas are potent photosensitizers. Until today there is no comparable selective fluorescent substance available for meningiomas. Nevertheless, there is a demand for intraoperative fluorescent identification of e.g. invasive skull base meningiomas to increase radicality. This study was established to investigate fluorescent image-guided resection with somatostatin receptor labelled fluorescence dye for intracranial meningioma in the nude mice.
Primary meningioma cell culture samples were stereotactically implanted subdural into 20 nude mice. 90 days after inoculation of the cells, a cranial MRI with contrast agent revealed tumor growth. After detection of tumor mass in MRI, FAM-TOC5,6-Carboxyfluoresceine-Tyr3-Octreotide was injected intravenously and tumor mass was hereafter resected under visualization via fluorescence microscope and endoscope. After attempted total resection, animal were sacrificed brain slices were obtained and histologically analysed to verify the resection extent.
In 18 mice tumor growth was detected in MRI after 90 days of inoculation. The tumor mass could be clearly identified with fluorescence microscope and endoscope after injecting FAM-TOC5,6-Carboxyfluoresceine-Tyr3-Octreotide. The tumor margins could be better visualized. After fluorescence-guided resection no remaining tumor could be identified in histological analysis.
This study describes for the first time the use of FAM-TOC5,6-Carboxyfluoresceine-Tyr3-Octreotide and demonstrates its value of fluorescent identification of meningioma cells in vivo. Furthermore, the authors established a new experimental animal model for fluorescence meningioma surgery.
光动力剂在恶性颅肿瘤手术中的应用相当普遍。例如,恶性神经胶质瘤中的 5-氨基酮戊酸(5-ALA)诱导的卟啉是有效的光敏剂。直到今天,脑膜瘤还没有可比的选择性荧光物质。然而,人们对内窥镜下荧光识别侵袭性颅底脑膜瘤等需求增加了根治性。本研究旨在研究荧光引导切除带 somatostatin 受体标记荧光染料的颅内脑膜瘤在裸鼠中的应用。
将脑膜瘤原代细胞培养标本立体定向植入 20 只裸鼠硬膜下。细胞接种 90 天后,行颅 MRI 增强扫描显示肿瘤生长。在 MRI 检测到肿瘤后,静脉注射 FAM-TOC5,6-羧基荧光素-Tyr3-Octreotide,然后在荧光显微镜和内窥镜下切除肿瘤。在试图完全切除后,动物被处死,获得脑切片,并进行组织学分析以验证切除范围。
接种后 90 天,18 只小鼠的 MRI 检测到肿瘤生长。注射 FAM-TOC5,6-羧基荧光素-Tyr3-Octreotide 后,可通过荧光显微镜和内窥镜清晰识别肿瘤。肿瘤边界更易识别。荧光引导切除后,组织学分析未发现残留肿瘤。
本研究首次描述了 FAM-TOC5,6-羧基荧光素-Tyr3-Octreotide 的应用,并证明了其在体内荧光识别脑膜瘤细胞的价值。此外,作者建立了一种新的荧光脑膜瘤手术实验动物模型。